Los Angeles,
26
November
2018
|
05:00 PM
America/Los_Angeles

Study Identifies a Genetic Driver of Deadly Prostate Cancer

Findings in Mouse Study, if Confirmed in Humans, Could Lead to Better Ways to Fight Treatment-Resistant Tumors

A new study has identified a novel molecular driver of lethal prostate cancer, along with a molecule that could be used to attack it. The findings were made in laboratory mice. If confirmed in humans, they could lead to more effective ways to control certain aggressive types of prostate cancer, the second-leading cause of cancer death for men in the U.S.

Men whose prostate cancer tumors are localized typically survive many years after diagnosis, whether they have surgery, radiation therapy or no treatment at all. But for a minority of men whose cancer spreads to other parts of the body and resists hormone therapy, the prognosis is poor, with fewer than a third surviving five years after diagnosis. More than 29,000 men in the U.S. die from prostate cancer each year, according to the American Cancer Society.

"We need fresh strategies to prevent prostate cancer from turning deadly for the thousands of men whose disease metastasizes and withstands hormone therapy," said Michael Freeman, PhD, co-director of the Cancer Biology Program in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. Hormone therapy blocks the activity of male hormones, which fuel the growth of the most common type of prostate cancer.

Freeman was the corresponding author of the multi-institutional study, published in the journal Nature Medicine. The co-first authors were project scientist Mirja Rotinen, PhD, and Sungyong You, PhD, assistant professor of Surgery and Biomedical Sciences, both at Cedars-Sinai.

For the research, the team analyzed genetic and molecular data from cancer patients in a large database. They found evidence of elevated activity of the molecule Onecut2 in tumors of patients whose prostate cancer resisted hormone therapy. Onecut2, a type of transcription factor, is needed for the body to make certain proteins.

The team found Onecut2 interfered with the activity of androgen receptor proteins, ­the targets of hormone therapy for prostate cancer. This process could allow the cancer to become less dependent on hormones for growth. At the same time, Onecut2 drove some of the cancer cells to change into a more aggressive variety that resists hormone therapy. "These twin actions of Onecut2 could help explain how certain prostate cancers evade hormone therapy and turn more aggressive," said Freeman, professor of Surgery and Biomedical Sciences.

In additional experiments involving human tissue samples, pharmaceutical databases and laboratory animals, the investigators identified a compound, CSRM617, that counteracted Onecut2. They showed CSRM617 significantly reduced the size of prostate cancer metastases in mice. "Our research suggested that Onecut2 is a master regulator of lethal prostate cancer that may be a useful therapeutic target in up to a third of patients whose cancer spreads and evades hormone therapy," Freeman said.

Freeman also was the corresponding author of a recent study in the journal Cancer Researchthat identified a new method to gauge the aggressiveness of prostate cancer. This method is based on how stable the shapes of the cancer's cell nuclei are. Instability was associated with cancer types that spread. The investigators also found they could detect nuclei instability in the bloodstream through cells shed by the tumor. These findings could lead to less invasive techniques for identifying potentially dangerous prostate cancer and monitoring its progression through blood samples, the research team said.

"These discoveries are emblematic of the paradigm-shifting work that is being carried out in cancer at Cedars-Sinai," said Dan Theodorescu, MD, PhD, director of the cancer institute. "They show how our investigators are bridging scientific discovery to clinical development of novel therapies that will impact patients."

Funding (Nature Medicine): Research reported in this publication was supported by the U.S. Department of Defense under award numbers W81XWH-16-1-0567, DOD PC131996 , DOD PC130244 and W81XWH-14-1-0152, National Institutes of Health under award numbers 1R01CA143777, 1R01DK087806 and 2P01CA098912, National Cancer Institute of the NIH under award number U54 CA143931, Prostate Cancer Foundation, Spielberg Discovery Fund in Prostate Cancer Research, Jean Perkins Foundation, Movember/PCR GAP1 Unique TMAs Project, Urology Care Foundation Research Scholar Award and Chesapeake Urology Associates Research Scholar Fund, 2018 Donna and Jesse Garber Award for Cancer Research, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and Urology Care Foundation Research Scholars Program of AUA Western Section Research Scholar Fund.

Disclosure (Nature Medicine): Cedars-Sinai has pending patent applications PCT/US2017/034768 (Freeman/Rotinen/Murali/You) and US62/548,879 (Freeman/Rotinen/Murali/You) relevant to this study.

Funding (Cancer Research): Research reported in this publication was supported by the National Institutes of Health under award numbers R01 CA143777, R01 CA218526 and 2P01 CA098912, the U.S Department of Defense under award numbers W81XWH-16-1-0567, W81XWH-16-1-0397, W81XWH-15-1-0473 and PC151088, Ladies Auxiliary VFW Cancer Research Postdoctoral Fellowship, Urology Care Foundation Research Scholar Award and Chesapeake Urology Associates Research Scholar Fund, NSF CAREER Award from the National Science Foundation under award number DBI-1254185 to A.C. Rowat and the Farber Family Foundation.

Disclosure (Cancer Research): Edwin Posadas from Cedars-Sinai discloses his conflict of interest as an uncompensated advisory board member of CytoLumina Technologies Corp. Hsian-Rong Tseng from UCLA discloses his financial interest in CytoLumina Technologies Corp., given his role as the founder of the company.

# # #

DOI: 10.1158/0008-5472.CAN-18-0608 (Cancer Research)